Re: A Multicenter Randomized Phase II Trial of Lenvatinib plus Everolimus Versus Cabozantinib in Patients with Metastatic Clear Cell RCC that Progressed on PD-1 Immune Checkpoint Inhibition (LenCabo) [0.03%]
仑伐替尼联合依维莫司与卡博替尼治疗接受PD-1免疫检查点抑制剂治疗后进展的转移性透明细胞肾癌患者的多中心随机II期试验(LenCabo二期临床试验)：一项开放标签、活性对照研究
Wenhao Xu,Aihetaimujiang Anwaier,Siqi Zhou et al.
Wenhao Xu et al.
The Hype and the Hope: Where Do We Stand with Prostate-specific Membrane Antigen-targeted Fluorescence-guided Surgery? [0.03%]
前列腺特异性膜抗原靶向荧光引导手术的现状与展望
Vera A Ottens,Giuseppe Chiarelli,Roberto Contieri et al.
Vera A Ottens et al.
Early studies highlight the promise of prostate-specific membrane antigen-targeted fluorescence-guided surgery. Realization of the full potential of this strategy will require ongoing technical refinement and the integration of hybrid-guide...
Re: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer [0.03%]
关于维迪西妥加特瑞利治疗HER2表达的晚期尿路上皮癌
Giandomenico Roviello,Silvia Mancini,Lorenzo Antonuzzo
Giandomenico Roviello
Re: Open Versus Robotic-assisted Partial Nephrectomy in Patients with Intermediate/High-complexity Kidney Tumours: Final Results of the Randomised, Controlled, Open-label, Multicentre Trial OpeRa [0.03%]
中间/高复杂性肾脏肿瘤患者开放手术与机器人辅助部分肾切除术的对比：OpeRa随机对照多中心试验最终结果分析
Daniele Amparore,Eduard Roussel,Riccardo Campi;Young Academic Urologists Renal Cell Carcinoma Working Group
Daniele Amparore
Re: Oscar Buisan, Pol Servian, Sonia Pedreño-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.014 [0.03%]
刘斯万、波尔·塞维安、索尼娅·佩德雷诺-洛佩斯等。一项关于RUTI疫苗异源加强策略的新型研究，可提高非肌层浸润性膀胱癌患者卡介苗的疗效：RUTIVAC-1期试验。 Eur Urol. 在线发表。 https://doi.org/10.1016/j.eururo.2025.08.014
Harry Herr
Harry Herr
Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer [0.03%]
CTDNA指导下的肌层浸润性膀胱癌辅助阿特朱单抗治疗研究答复信
Giandomenico Roviello,Ismaela Anna Vascotto,Lorenzo Antonuzzo
Giandomenico Roviello
Re: ACOX2 Destabilizes the MRE11-RAD50-NBS1 Complex and Boosts Anticancer Immunity via the cGAS-STING Pathway in Clear Cell Renal Cell Carcinoma [0.03%]
ACOX2通过cGAS-STING途径破坏MRE11-RAD50-NBS1复合物并增强透明细胞肾细胞癌的抗癌免疫反应
Hangbiao Zhang,Yifan Liu,Jialin Zhou et al.
Hangbiao Zhang et al.
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial [0.03%]
根治术后生化复发前列腺癌患者高剂量化疗 vs 标准剂量挽救性放疗：SAKK 09/10 随机 III 期临床试验的长期数据
Pirus Ghadjar,Stefanie Hayoz,Daniel R Zwahlen et al.
Pirus Ghadjar et al.
We report long-term outcomes from the phase 3 SAKK 09/10 trial that randomly assigned men with biochemical progression after radical prostatectomy to conventional-dose (64 Gy) or dose-intensified (70 Gy) salvage radiotherapy (SRT) to the pr...
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials [0.03%]
联合卡介苗(BCG)用于高危初治非肌层浸润性膀胱癌的疗效和安全性：ALBAN、CREST及POTOMAC试验结果汇总分析
Pietro Scilipoti,Paolo Zaurito,Mattia Longoni et al.
Pietro Scilipoti et al.
Intravesical bacillus Calmette-Guérin (BCG) therapy remains the cornerstone for high-risk non-muscle-invasive bladder cancer (NMIBC), but up to 40% of patients experience disease recurrence or progression within 2 yr. We conducted a system...
Reply to Gonglin Tang and Hongwei Zhao's Letter to the Editor re: Nikhil Mayor, Alexander Light, Anna Silvanto, et al. IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy. Eur Urol. In press. https://doi.org/ [0.03%]
Gonglin Tang和Hongwei Zhao来信答复有关Nikhil Mayor，Alexander Light，Anna Silvanto等人(《IP8-FLUORESCE：前瞻性配对队列研究，评估荧光共聚焦显微镜在根治性前列腺切除术中实时评估手术切缘的诊断准确性》欧洲泌尿外科，在线出版。)
Nikhil Mayor,Anna Silvanto,Greg Shaw et al.
Nikhil Mayor et al.